Form 4: Clene Inc. Chief Science Officer Granted Stock Options

Mark Mortenson, Chief Science Officer of Clene Inc., was granted stock options for 2,800,000 shares of common stock on June 7, 2024.

Summary

• Mark Mortenson, the Chief Science Officer of Clene Inc., received stock options on June 7, 2024.
• He was granted options for 2,000,000 shares under the Clene Inc. Amended 2020 Stock Plan with an exercise price of $0.37 per share.
• Vesting for these options is contingent upon Clene Inc. achieving certain milestones related to FDA approval and revenue generation.
• Specifically, 33.3% vests upon FDA acceptance of an NDA, another 33.3% upon FDA approval of an NDA, and the remaining 33.4% upon achieving $100,000,000 in revenues from approved drug sales.
• Additionally, Mortenson received options for 800,000 shares under the same stock plan, also at an exercise price of $0.37 per share.
• These options vest with 25% vesting on June 7, 2025, and the remainder vesting in 36 equal monthly installments starting July 7, 2025.
• The options expire on June 6, 2034.

Sentiment

Score: 7

Explanation: The announcement is generally positive as it incentivizes the Chief Science Officer to achieve key milestones. However, the vesting is contingent on future success, introducing some uncertainty.

Positives

• The vesting schedule for a portion of the options is tied to significant milestones such as FDA NDA acceptance and approval, aligning Mortenson's interests with the company's success.
• The staggered vesting schedule for the other portion of the options encourages long-term commitment from the Chief Science Officer.

Risks

• The vesting of a significant portion of the options depends on FDA approval and revenue targets, which are subject to regulatory and market risks.
• Failure to achieve these milestones could result in the options not fully vesting.

Future Outlook

The vesting of the options is tied to future events, including FDA approval of an NDA and achieving $100,000,000 in revenue, indicating the company's focus on these goals.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders. The vesting conditions tied to regulatory milestones are typical for companies seeking drug approvals.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• Companies like BioNTech and Moderna also use stock options with vesting schedules tied to milestones such as clinical trial results and regulatory approvals.
• The size of the grant (2,800,000 shares) and the exercise price ($0.37) would need to be compared to similar grants at peer companies to assess its relative value and potential impact on shareholder dilution.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns management's interests with the company's success.
• Employees may be motivated by the potential for future success and the achievement of key milestones.

Key Dates